Compare Novo Nordisk A/S (NVO) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs VF Corp — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while VF Corp trades at $16.88 (market cap $6.62B). The key difference: Novo Nordisk A/S is far larger — about 33.3× VF Corp's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | VFC | |
|---|---|---|
Market Cap | $220.53B | $6.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $21.55 |
52-Week Low | $35.29 | $11.66 |
Enterprise Value | $239.49B | $10.77B |
Dividend Yield | 3.63% | 2.13% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
